Dr. Al Sandrock
our novel currently represent enable tracer Novartis from We progressing exercise the breakthrough organs. pleased in of of the system ongoing the several hamper will afternoon, that derived the these gene extremely as Voyager's have We and new everyone. proprietary as well other to well. to therapy certain recently good will to that fundamental leverage gene including is signed at and the next address our TRACER milestones that platform the plan We are quarters. I'm that capsids believe nervous life-changing our of we capsids, Both transformational field limitations innovation mission discovery Pfizer some capsids Julie, that up pioneer believe the therapy. those therapies. partners the discuss Voyager. and capsids collaborations Thanks, coming for involving gene development advance central developments AAV with to hope option exciting
earlier cash after as prioritized Today, our treatment Soon builds to and R&D on is joining announce transformational patients development we diseases. programs value evaluate with I important Gene XXXX. A a therapy many are for therapies has potential serious where shareholder focus the with the creating pipeline, to the runway to had Company comprehensive that into year, Zolgensma CEO of process treatment and with impact which of led for this goal growing advances maintaining capsids. excited our muscular TRACER determine to of infants of new while the CNS the the that clear spinal example made we've this our Voyager's transform atrophy.
on panel the are spinal CSF being these such intrathecally into in we believe at use as study or have to used the to limits left the of We space methods primate from brain GFP, therapy literature space on humans. Consequently, this blood-brain slide a to similar comes and adults. multiple intravenous levels. Example or two. of cynomolgus employed or in injected into fluid methods X, fluorescent into which and CSF been of examples experiments. monkeys, analogous in from the the show cerebral direct spinal injection are parenchyma On gene attempted. Slide The appears label the AAVX However, green situation the use therapy protein, published is expressing FDA the what is delivery happens are in methods barrier children Zolgensma preclude up the older gene in nonhuman of age published delivery when the when
is cortex the comes limitation published site this In is regions. pattern directly seen benefit. expression, to injected The there for surgical magna the diseases means of which by parenchyma. drop-off into the result by likely the levels stain even see structures most cerebral to limitations the involve may procedure. and expressing utility. panel therapeutic AAVX in case, of brain the spaces, entire precludes applications, and the of this the number green study areas GFP from CNS as risk of transduction in distribution better. CNS that staining, delivery to spinal a therapy so significant a brain, Injections the a is not some into more limited sell you As the are of although to likely deep clear Clearly, convection-enhanced result Moreover, in is from CSF and GFP few highly other as lumbar such low for are go methods putamen in even the here localized distribution. intraparenchymal delivery in and the benefit of you most with cord localized brown transduced begin patchy localized severe where less likely injections, highly brain, the brain, much gene disease the from eventually the by other in cisterna a was a gray rostral weekly imposes injection, efficiency can cells, there cells number major as of such on stain right of clinical distribution be
capsids improved novel potential solution the became an to CNS been limitations Voyager approach capsid than primates capsids do delivery several in shown believe more capsid in could TRACER, now As be proprietary to novel our conventional with these set that and as out efficiently clear the transduction This capsids AAVX of increasingly distribution driven our has TRACER resulted the select that a advantages. variants invented core distinct target other to interest. has TRACER has use nonhuman known any past preferentially We in as more of we allowed in tissues that far is vivo capsids evaluate CNS approach years, platform over have enabled tropism XX tissue scientists two This organ. We increased those delivery discover which AAVX of and IV platform. our challenges. to target expression than in the to identify to today. display team scientists only and screening of after that AAV the has better. million transduce At
a screens capsids that related which that show may not we very series species screening us the along that to performed well has tropism mice selecting improved activity so nonhuman only with closely for subsequent allow humans, taught -- to past work may we're in in experience beings. may non-capsids First, that species primates, of human initial that translate other only in show in
measure Second, tissue, remarkable. we The messenger the have mRNA capsids not is we express enter been the selecting we but RNA. each When that of into level the have of in barrier, of confidence from that payload their target get cells step brain evaluating that our are also the the performance at productively. at capsids screening only TRACER desired blood of process and results we across the measure expression that gene production by deliver and
we compared AAV more displayed capsids as the than to have have X thus in conventional transgene nonhuman brain the novel capsid in TRACER. with capsids observed XXX-fold expression derived the of Slide highlights Our primates. far higher from what some
time, Remarkably, or efficiently capsids while types. liver cell efficiently our the therapeutically cells cortex, same that both cell targeting that [RCAF] the capsids the in neurons de-target and ganglion of our transduce and cord can and the root neurons, in We can novel have delivery. may such after result they glia cellular also CNS, At relevant found dorsal toxicity, including at brain, numerous increased can hippocampus the neurons. of as spinal glia target regions IV level, cerebral
our the adequately we species, receptor that to available one finding our we've have using could TRACER found with the further this enable very of recently capsids the further details which capsids. improved demonstrate the conventional can Finally, believe binds of in capsids, In data pleased that addressed believe and marmoset increases isoform a therapeutic probability CNS believe that most scientific CNS have to we We also data capsids. identification truly currently receptor for summary, this types. our as that into capsid receptor of the capsid expressed will across AAV upcoming we this one blood-brain show likelihood CNS including diseases cross conference. tropism data binding today which of capsid the many that barrier potential characterization can capsids not a of strong We're tell on and promising the identify brain for is we improves candidates humans. What I identified an unique the announce that human of our mouse, to plan provide we that today the for the be have interaction We also AAV cell cells is that such in to receptor, humans. our translation other the supporting the endothelial in macaque, you promising that
Importantly, have for receptor explore now that pressing can capsids. platform underway of I've Moreover, are rational the the CNS resulted believe oligonucleotides. we therapeutic path TRACER this of to modalities our therapy possibility the of of treat as experiments other discovery and the discussed such may may facing in antibodies diseases. delivery the this provide CNS tremendous potential CNS enable hurdles human to a proteins, most design generation gene BBB-penetrant has that and how IV-delivered capsids some overcome
combining knowledge unique development I therapies our are with potentially aim the drug with disease our We discuss against CNS deep these now team's impact. and clinical transformative biology TRACER targets well-validated now pipeline. will of capsids with of developing
pipeline. how Before tell to I'd doing like prioritize we the you so,
we patients high if have diseases few, life-threatening First, where treatment medical with unmet options. chose needs, any, diseases serious
targets and disease-causing well-validated those are these we indicates data Second, pathologic human targets that we validated pathways. human dealing clinical with genetics chose for biological in by that diseases,
silencing programs commercial for and opportunities. our should that anti-tau are these be SODX passive Fourth, finally, robust pharmacology. ALS early evidence now programs Third, mediated possible we GBAX immunotherapy gene chose on priorities. or selected Based criteria, top And would at where establish phase in had trials. programs meaningful to biology clinical SODX of for disease. we proof-of-concept proof we on where it replacement provide rapidly Parkinson's and focused Alzheimer's gene least programs efficiently of preclinical disease, for we three
We will day development. toward internal pipeline these to We in prioritized advance to focus will we that programs, programs addition discussion prioritized note our plans and continue today's our also each clinical on hope research programs of for early research into future. stages We be Huntington's to to later the conduct vectorize and one to able antibodies. HERX on disease gene in advance therapy these
in mutations common which of factor, also a neurodegenerative therapeutic mutations toxic start in in development lysosomal mutation of have of in internal in disease. GBAX, nigra with alone. Homozygous hypothesize alpha-synuclein a of disease the mutation detail. GCase Let's evidence risk XX-fold. more common in to Parkinson's Up there in lysosomal restoration benefit. loss substrates disease, of Parkinson's the GBA patients of Parkinson's have patients absence where GCase that most the be or disease. resulting and of impacting prioritized GCase, GBAX is GCase disease even with disease programs risk there increased XX% We disease The GBAX most X disease, the of now is substantia loss program. neurons. with to risk GBAX resulted review accumulation our heterozygous growing disease the GCase are to encodes to patients the decreasing may the substrates. of U.S. aggregates, function idiopathic which GBAX approximately in each function leads an GBAX dysfunction glycosphingolipid of Gaucher's Moreover, the will I'll the of the about glycosphingolipid second Parkinson's disease function of Loss lysosomal mutations. evidence people enzyme, million and degrades of and with of genetic idiopathic restoration is storage mutation, general Parkinson's glucocerebrosidase benefit loss in PD, Parkinson's the thought
who program alluded because Parkinson's XX, on provides As is patients. Consequently, nigra carriers. on had sorry, evidence earlier, patients did shown relative GBAX such as on the protein the Slide and brain the gene GCase the substantia enzyme GBAX derived for in the left not capsids, -- the panel who biology of TRACER results in development shown with manner. CSF and in brain in the mutations, proof glucosylsphingosine in fall cerebral Slide forward relevant GCase early as XX. regions our ASGCT with the This If of as brain in the patients that activity gene left on PD of control brain, an in shown or demonstrate We the derisking. activity we mutation. to mutations GBAX meeting of GCase the therapy phase enzymes glucosylceramide Slide the restores who Slide panel, lowers who the should fluid In substrates this on PD have presented harbor Interestingly, XX, and of loss GCase a GBA showed there's enzyme in activity the the level reduced levels study are as early This opportunity achieve an shown spinal are similar an year, thus glucosylceramide providing GCase rodents are to of gene function Lewy is preclinical clinical panel elevated this on dementia substrate hope in even disease increases the replacement in to a as reduced right clinical and shown normal, to bodies to therapy trial. our of dose-dependent on there patients in XX. in delivered one to in Sciences expression potential a Voyager IV clinic moving in both at path
of We we of selection in evaluating a selecting In year-end. IV XXXX, are expect candidate. of finalize program anticipation development TRACER by to capsid first the delivered for half this capsids an
line the we the on XXXX. actively expect puts a XXXX, GLP finding second initiate time track reviewing IND in studies study to that, us initiating XXXX, of are accelerate Following for half in nonhuman we we primates, This toxicology in an in and to options anticipate but dose-range program.
to motor there therapies. now great to final improved function a gain entire stem by for cerebral diagnosis. SODX system, central lateral typically amyotrophic SODX the rapidly that with the disease brain benefit a cortex. we the development as reducing length death ALS clinical superoxide thought therapeutic of the can toxic three expression as ability well to development. leads of engagement mutations years as a and SODX-ALS, measure biomarker is reduced motor dismutase levels as plasma a neurons From believe court, treatments leads SODX as of effective, standpoint, mutations. Moving nervous light clinical is sclerosis progressing and facilitate demonstrate after are neurodegenerative well to are provide as in approximately of the that in greatly neurofilament Burn of that one of the dominant Autosomal to in efficacy need cause the to CSF chain target We biomarker ability degeneration clinical a the to the a along surrogate patients neurons minimally upper the
hope leads delivery significant this weight knockdown in that We as program, of therapy eager ASGCT disease broad believe in presented XX spinal involving cord BBB and combines the for shows delivered brainstem advance at SOD data spinal improvements all entire CNS-tropic and Slide milestones were brain, to preclinical provide support all approach Preclinical the we are the cord year, IV for that shown therapeutic siRNA on the which the regions the to siRNA toward our with namely XX the with capsid. earlier the data anticipated GXXA derived motor ALS conference CNS targeting, demonstrates TRACER robust penetrant approach, potent SODX IV body and gene mouse Because performance, the of capsid. model. and neuraxis, a follows. an for a these Our clinic. potential for construct, in Slide SODX to of survival major address pharmacologic we are of manifestations, this
study end year. primate is of nonhuman and range our founding initiation to transition half readout team dose achieve this plan first we evaluation on a anticipated. finding study these of XXXX. I'll is our -- anticipate select filing tau. ranging of the we a conducted program of we XXXX capsid obtain based days candidate is in since by NHP toxicology We now of Our passive company. the the second final expect and study in dose manner, to underway, This milestones research the of timely in XXXX, If in immunotherapy earliest program IND our half an to targeting the GLP
Robust of discovery favorable work including targeting disease. in antibodies pathological number Alzheimer's supporting models towel. a selectively the continued development. Our These a of for tau led efficacy of antibody novel affinity tau, characteristics neurodegenerative antibodies have tau been that vectorization to high animal include of discovery of pathological These to number a spreading. protein for linked diseases, has
leverage that plan be as has immunotherapy. anti-tau an We approach clear are ineffective. antibodies, an to anti-Tau We shown This to to been the have first potential from including those antibody IV clinically other clinical with way also for lead candidates. an and disease Alzheimer's to tremendous lead vectorization tauopathies of the as unmet candidates eventual these therapy for high-value may other of antibodies It the need. treatment gene differentiation
the pathology demonstrated approach of Some Those time disease. the investigators of known administration neurodegenerative of have brain pathology Slide imaging phase that to correlating use spread that any have early PET have left demonstration of accumulation impairment Alzheimer's of several feasibility disease as Alzheimer's and important the PET the with allow amyloid immunotherapies of regions clinical directed already diseases shown studies, dementia by also controlled XX, shown impairment images increased in disease have We've biomarkers. standpoint also proof of a which the XX-month an tau in shown in recent and stereotype with of to that this better trials. the Alzheimer's should Moreover, of for IV patients in produce shown -- the with therapies for across such brain XX XX- on work out biology assessment fashion some propagates imaging to now In other are seminal pointed for and shown advantages certain stage. and spread effects a as as panel important longitudinal of rapid evaluating that tau Modern of on trial. course example, to [indiscernible]. been plan over tau the from PET years, development with tau efficient and of taupathologi we the cognitive than trials in have as correlates demonstrated pathology tau Slide broad advancing due mild spread tau of
tau on may an may this extracellular have of tau antibodies, as Our that diseases the targeting of been efficacy. the several right side not the that including therapeutic as those has hypothesis shown slide, spread neuron-to-neuron clinical and disease. has been block Alzheimer's the tau sites plausible of demonstrated antibody progression several attenuate at monoclonal of this target such
mouse meeting efficacy the We are XX on be shows also patients. which, side significant pathological the began tested to ipsilateral model, tau. In differentiate in and just Slide this failed it in on tau later. animal antibody brain the substantial the of Alzheimer's XXXX show slide, efficacy shown in seven-week hippocampus mutant on be is well very and left continued the can our targets to strain right targeting for contralateral were at we're both from immunized filament expresses II Voyager This sacrifice Of trial form ipsilateral contralateral EPHF that paired AAIC in IPNXXX a panel studies, one of trial, of published a the has hippocampus. tissue similar slide of our and was called not that pathology in to then this internal pathological the right on from of rosy and been animals EPHF, in data and well-controlled sorry, that a by In the had tau tau spreads failed And and our side old PXXXS efficacy this reduction of tau measured aware experiment. in in Phase pathological the to antibody antibodies tau trial. injected C called mouse, six has figure dosing Phase differentiated into contrast, in antibody injected disease that antibodies of antibody equivalent pathological clinical is in extracted to where as seating II from a show induces of San week, antibody clinical enriched been in the Diego. we in tau epitope. is tau the to immunotherapy. presented these clinic, model helical antibody accumulation and material hippocampus. -- this, from of IPNXXX different these terminal pathological been knowledge, The accumulate formation careful the tested has a mice terms and one tau betting the activity ineffective when a human a panel been note, the hippocampus. to dosing afterward mouse Levels and There of contralateral the In weeks in also on tested This the has studies, the the in humanized. shown when terminal a with biological
have experiments targeting blocking result spread the believe C-terminal such and antibody N-terminal brain. advantage the an these, a As pathological in Voyager of tau may the antibodies of the as targeting we that over by
advancing is We immunotherapy clinic program of already our toward the antibody and humanization our are underway. murine anti-tau
followed achieve in results. to studies target later half timely selection XXXX. initiation call Looking If we first toxicology pass in to Julie we I'll financial review the a year. of filing by candidate manner, ahead, GLP these we that development now anticipate IND in a of of the our XXXX, would milestones
